Reported about 8 hours ago
In a recent discussion, Jim Cramer expressed a preference for Eli Lilly over Viking Therapeutics (VKTX), which has seen a significant decline of over 52%. While VKTX is involved in developing treatments for metabolic disorders, Cramer believes that Eli Lilly presents a more favorable investment opportunity at this time, especially as interest in VKTX wanes amidst uncertainty about potential takeover talks.
Source: YAHOO